Rolke James 4
4 · LA JOLLA PHARMACEUTICAL CO · Filed Mar 16, 2020
Insider Transaction Report
Form 4
Rolke James
Chief Scientific Officer
Transactions
- Award
Stock Option (Right to Buy)
2020-03-13+241→ 241 totalExercise: $4.00Exp: 2030-03-13→ Common Stock (241 underlying) - Award
Common Stock
2020-03-13$3.40/sh+241$819→ 80,918 total
Footnotes (2)
- [F1]These shares were acquired on 03/13/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.